Together, our genome-wide CRISPR-Cas9 loss-of-function genetic screen successfully revealed both known and potential synthetic lethal vulnerabilities with EGFR TKI as well as modes of resistance in EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.